Immunic (NASDAQ:IMUX) Upgraded to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Guggenheim assumed coverage on shares of Immunic in a research note on Tuesday, March 24th. They set a “buy” rating and a $70.00 price objective for the company. upgraded shares of Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. HC Wainwright restated a “buy” rating and set a $22.00 price objective (up from $5.00) on shares of Immunic in a research note on Thursday. Finally, D. Boral Capital downgraded shares of Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $52.43.

Immunic Trading Up 0.9%

Shares of Immunic stock traded up $0.10 during trading hours on Monday, reaching $10.72. 40,280 shares of the company’s stock were exchanged, compared to its average volume of 338,823. The company has a 50 day moving average of $11.07 and a two-hundred day moving average of $8.40. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $15.10. The stock has a market cap of $145.99 million, a P/E ratio of -1.52 and a beta of 1.20.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.18). As a group, analysts expect that Immunic will post -3.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. Nantahala Capital Management LLC bought a new stake in shares of Immunic in the 4th quarter valued at about $2,337,000. Millennium Management LLC raised its holdings in Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after acquiring an additional 2,888,829 shares during the period. Laurion Capital Management LP raised its holdings in Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares during the period. Marshall Wace LLP raised its holdings in Immunic by 91.2% in the 4th quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock valued at $541,000 after acquiring an additional 486,468 shares during the period. Finally, Simplify Asset Management Inc. bought a new position in Immunic in the 1st quarter valued at about $487,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.